{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:50:53Z","timestamp":1790974253779,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00277-015-2303-5","type":"journal-article","created":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T06:03:51Z","timestamp":1422857031000},"page":"981-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis"],"prefix":"10.1007","volume":"94","author":[{"given":"K.","family":"Lerch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pezzutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. W.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"2303_CR1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G et al (2011) Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42\u201351. doi: 10.1016\/S0140-6736(10)62175-7","journal-title":"Lancet"},{"key":"2303_CR2","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986\u20131992. doi: 10.1200\/JCO.2006.06.4618","journal-title":"J Clin Oncol"},{"key":"2303_CR3","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725\u20133732. doi: 10.1182\/blood-2005-01-0016","journal-title":"Blood"},{"key":"2303_CR4","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579\u20134586. doi: 10.1200\/JCO.2007.13.5376","journal-title":"J Clin Oncol"},{"key":"2303_CR5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210. doi: 10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"key":"2303_CR6","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944\u20132952. doi: 10.1182\/blood-2013-11-531327","journal-title":"Blood"},{"key":"2303_CR7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK et al (2014) PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370:1008\u20131018. doi: 10.1056\/NEJMoa1314583","journal-title":"N Engl J Med"},{"key":"2303_CR8","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ et al (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:5165\u20135169. doi: 10.1200\/JCO.2008.16.0283","journal-title":"J Clin Oncol"},{"key":"2303_CR9","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","volume":"25","author":"S Montoto","year":"2007","unstructured":"Montoto S et al (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426\u20132433. doi: 10.1200\/JCO.2006.09.3260","journal-title":"J Clin Oncol"},{"key":"2303_CR10","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","volume":"15","author":"Y Bastion","year":"1997","unstructured":"Bastion Y et al (1997) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587\u20131594","journal-title":"J Clin Oncol"},{"key":"2303_CR11","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK et al (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31:3272\u20133278. doi: 10.1200\/JCO.2012.48.3990","journal-title":"J Clin Oncol"},{"key":"2303_CR12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","volume":"17","author":"E Gine","year":"2006","unstructured":"Gine E et al (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17:1539\u20131545. doi: 10.1093\/annonc\/mdl162","journal-title":"Ann Oncol"},{"key":"2303_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.1983.1.1.11","volume":"1","author":"B Acker","year":"1983","unstructured":"Acker B et al (1983) Histologic conversion in the non-Hodgkin\u2019s lymphomas. J Clin Oncol 1:11\u201316","journal-title":"J Clin Oncol"},{"key":"2303_CR14","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.1995.13.7.1726","volume":"13","author":"AR Yuen","year":"1995","unstructured":"Yuen AR et al (1995) Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13:1726\u20131733","journal-title":"J Clin Oncol"},{"key":"2303_CR15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2141.2010.08519.x","volume":"152","author":"MB Eide","year":"2011","unstructured":"Eide MB et al (2011) High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol 152:600\u2013610. doi: 10.1111\/j.1365-2141.2010.08519.x","journal-title":"Br J Haematol"},{"key":"2303_CR16","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","volume":"31","author":"D Villa","year":"2013","unstructured":"Villa D et al (2013) Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol 31:1164\u20131171. doi: 10.1200\/JCO.2012.44.0693","journal-title":"J Clin Oncol"},{"key":"2303_CR17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1600-0609.2008.01146.x","volume":"81","author":"M Hamadani","year":"2008","unstructured":"Hamadani M et al (2008) High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol 81:425\u2013431. doi: 10.1111\/j.1600-0609.2008.01146.x","journal-title":"Eur J Haematol"},{"key":"2303_CR18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.bmt.1705178","volume":"36","author":"C Andreadis","year":"2005","unstructured":"Andreadis C et al (2005) Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant 36:955\u2013961. doi: 10.1038\/sj.bmt.1705178","journal-title":"Bone Marrow Transplant"},{"key":"2303_CR19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","volume":"19","author":"CD Williams","year":"2001","unstructured":"Williams CD et al (2001) High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin\u2019s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19:727\u2013735","journal-title":"J Clin Oncol"},{"key":"2303_CR20","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/annonc\/mdt029","volume":"24","author":"D Villa","year":"2013","unstructured":"Villa D et al (2013) Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. Ann Oncol 24:1603\u20131609. doi: 10.1093\/annonc\/mdt029","journal-title":"Ann Oncol"},{"key":"2303_CR21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","volume":"157","author":"A Conconi","year":"2012","unstructured":"Conconi A et al (2012) Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 157:188\u2013196. doi: 10.1111\/j.1365-2141.2012.09054.x","journal-title":"Br J Haematol"},{"key":"2303_CR22","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184\u20134190. doi: 10.1200\/JCO.2010.28.1618","journal-title":"J Clin Oncol"},{"key":"2303_CR23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1995.364","volume":"72","author":"DG Altman","year":"1995","unstructured":"Altman DG et al (1995) Review of survival analyses published in cancer journals. Br J Cancer 72:511\u2013518","journal-title":"Br J Cancer"},{"key":"2303_CR24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"D Cox","year":"1972","unstructured":"Cox D (1972) Regression models and life tables. J R Stat Soc 34:187\u2013220","journal-title":"J R Stat Soc"},{"key":"2303_CR25","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258\u20131265. doi: 10.1182\/blood-2003-12-4434","journal-title":"Blood"},{"key":"2303_CR26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"M Shipp","year":"1993","unstructured":"Shipp M, Harrington D, Anderson J (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 329:987\u2013994","journal-title":"N Engl J Med"},{"key":"2303_CR27","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","volume":"123","author":"M Pfreundschuh","year":"2014","unstructured":"Pfreundschuh M et al (2014) Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 123:640\u2013646. doi: 10.1182\/blood-2013-07-517037","journal-title":"Blood"},{"key":"2303_CR28","doi-asserted-by":"crossref","first-page":"908191","DOI":"10.1155\/2013\/908191","volume":"2013","author":"M Ozbalak","year":"2013","unstructured":"Ozbalak M et al (2013) Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study. ISRN Hematol 2013:908191. doi: 10.1155\/2013\/908191","journal-title":"ISRN Hematol"},{"key":"2303_CR29","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857\u20131861. doi: 10.1182\/blood-2006-08-038257","journal-title":"Blood"},{"key":"2303_CR30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mds433","volume":"24","author":"P Bains","year":"2013","unstructured":"Bains P et al (2013) Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol 24:428\u2013432. doi: 10.1093\/annonc\/mds433","journal-title":"Ann Oncol"},{"key":"2303_CR31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/10428194.2011.631637","volume":"53","author":"M Ban-Hoefen","year":"2012","unstructured":"Ban-Hoefen M et al (2012) High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma 53:830\u2013835. doi: 10.3109\/10428194.2011.631637","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2303-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2303-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2303-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T23:15:53Z","timestamp":1717715753000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2303-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["2303"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2303-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,3]]}}}